Succinic acid.

Succinate cannot be oxidised without ubiquinone waiting to accept the electrons. Complex II has no proton-pumping step of its own, so ubiquinone is the entire downstream route for succinate-derived reducing equivalents. This is settled textbook biochemistry, not a claim that taking both raises anything measurable in a person. Ubiquinone status in tissue is not obviously limiting in healthy adults.

Riboflavin is converted to FAD, and FAD is the hydrogen acceptor that strips two electrons off succinate to make fumarate. Without adequate riboflavin, complex II assembly and activity fall. This is a cofactor dependency rather than a dose-response benefit, so it matters most where riboflavin intake is low.

The electron path from succinate runs FAD, then 2Fe-2S, 4Fe-4S and 3Fe-4S clusters, then ubiquinone. Iron availability governs assembly of those clusters. Low iron status therefore constrains succinate oxidation at the enzyme level. This says nothing about whether supplementing either changes a whole-body outcome.

Glutamine is the main anaplerotic substrate topping up cycle intermediates in most tissues. Its carbon arrives upstream of succinate, so glutamine availability sets part of the endogenous succinate supply. Adding exogenous succinate does not substitute for that, since the entry points differ. The relationship is directional and worth stating rather than a combination effect.

Succinate is made from succinyl-CoA, and succinyl-CoA comes from alpha-ketoglutarate via a lipoate-dependent dehydrogenase. That places lipoic acid one enzyme upstream of the endogenous succinate pool. Supplemental lipoic acid is largely used as a free radical scavenger rather than incorporated as enzyme cofactor, so the practical overlap is smaller than the diagram suggests.

Malate and succinate occupy adjacent positions in the same cycle and are often stacked in pre-workout formulas on that basis. Whether adding two intermediates does more than adding one has not been demonstrated in people. Human ergogenic data on succinate itself is thin, as its own systematic review makes clear. The pairing is chemically coherent and clinically unresolved.

Free succinic acid is sour and locally irritating to the stomach lining at higher doses. Neutralising it to disodium succinate removes the acid load and improves palatability in effervescent products. This is a formulation choice about tolerability, not about how much reaches the mitochondria. Bicarbonate also carries its own sodium load worth counting.

Organic acid salts of magnesium dissolve more readily than the oxide at gastric pH, which is the usual reason for choosing them. In magnesium succinate the succinate is the counter-ion, present in a small amount relative to any standalone succinate dose. Do not count a magnesium succinate capsule as a meaningful source of succinate. It is a delivery decision for the mineral.

Isocitrate, alpha-ketoglutarate and malate dehydrogenases all reduce NAD+, while succinate dehydrogenase reduces FAD. That difference is why succinate contributes fewer ATP equivalents per molecule oxidised than the NAD-linked intermediates. Anyone stacking cycle intermediates with NAD precursors should know the two feed the electron transport chain at different entry points. This is an explanation, not a combination claim.